

Datasheet: HCA283P

Description:	HUMAN ANTI DENOSUMAB:HRP
Specificity:	DENOSUMAB
Other names:	PROLIA, XGEVA
Format:	HRP
Product Type:	Monoclonal Antibody
Clone:	AbD26781_hIgG1
Isotype:	IgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	■			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form

Human IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line. Conjugated to horseradish peroxidase (HRP) – liquid

Preparation

Purified IgG prepared by affinity chromatography on Protein A

Buffer Solution

Phosphate buffered saline

Preservative Stabilisers

0.01% Thiomersal

Approx. Protein Concentrations

IgG concentration 0.1 mg/ml

Immunogen

Denosumab

Specificity

Human Anti-Denosumab Antibody, clone AbD26781_hIgG1 is a non-inhibitory anti-idiotypic antibody that specifically recognizes free human monoclonal antibody drug denosumab, and the drug in complex with its target, RANKL (receptor activator of nuclear factor kappa-B ligand). The antibody does not recognize free RANKL and does not inhibit binding of denosumab to RANKL.

A pair of anti-denosumab antibodies can be used to develop a pharmacokinetic (PK) bridging assay. This antibody clone AbD26781_hIgG1 is recommended as the detection antibody, paired with either clone AbD26295_hIgG1 ([HCA280](#)) or clone AbD26862_hIgG1 ([HCA282](#)) as capture

antibody. It can also be used as the detection antibody in an antigen capture format assay. This antibody is not suitable for the development of an anti-drug antibody (ADA) assay.

Denosumab (Prolia, Xgeva) is a fully human monoclonal antibody (IgG2/kappa) for the treatment of osteoporosis, treatment-induced bone loss, bone metastases, multiple myeloma, and giant cell tumor of bone. The drug specifically binds to human RANKL a protein that acts as the primary signal to promote bone removal/resorption and prevents RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors.

[View a summary of all anti-denosumab antibodies.](#)

Affinity	The monovalent intrinsic affinity of this antibody was measured as $K_D=19$ nM by real time, label-free molecular interaction analysis on immobilized denosumab, and as $K_D =17$ nM on the RANKL/drug complex.
ELISA	This antibody can be used as a detection antibody in a bridging ELISA together with HCA280 (clone AbD26295_hlgG1) or HCA282 (clone AbD26862_hlgG1) as capture reagents. This antibody can be used in an antigen capture ELISA. Protocol: PK bridging ELISA to measure free drug.
Storage	Store at -70°C . Storage in frost-free freezers is not recommended. This product should be stored undiluted. This product is photosensitive and should be protected from light. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Guarantee	12 months from date of despatch
Acknowledgements	Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Prolia and Xgeva are registered trademarks of Amgen Inc.
Health And Safety Information	Material Safety Datasheet documentation #10094 available at: 10094: https://www.bio-rad-antibodies.com/uploads/MSDS/10094.pdf
Licensed Use	For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad
Regulatory	For research purposes only
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual

Related Products

Recommended Useful Reagents

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

[HUMAN ANTI DENOSUMAB \(HCA280\)](#)

[HUMAN ANTI DENOSUMAB \(HCA282\)](#)

'M371722:200612'

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

Printed on 11 Aug 2020

© 2020 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)